Jan 22, 2019 7:45am EST DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
Jan 09, 2019 5:00pm EST DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
Jan 03, 2019 8:09am EST DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
Nov 12, 2018 4:45pm EST DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
Nov 06, 2018 5:00pm EST DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
Sep 27, 2018 7:38am EDT DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
Sep 05, 2018 8:00am EDT DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
May 03, 2018 8:30am EDT DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
Apr 05, 2018 7:15am EDT DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
